Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics
Open accessThe DOI matches its Crossref record; 151 of the 154 references it cites were found in a registry or an index.
Abstract
Exosomes (EXOs) were given attention as an extracellular vesicle (EV) with a pivotal pathophysiological role in the development of certain neurodegenerative disorders (NDD), such as Parkinson’s and Alzheimer’s disease (AD). EXOs have shown the potential to carry pathological and therapeutic cargo; thus, researchers have harnessed EXOs in drug delivery applications. EXOs have shown low immunogenicity as natural drug delivery vehicles, thus ensuring efficient drug delivery without causing significant adverse reactions. Recently, EXOs provided potential drug delivery opportunities in AD and promising future clinical applications with the diagnosis of NDD and were studied for their usefulness in disease detection and prediction prior to the emergence of symptoms. In the future, the microfluidics technique will play an essential role in isolating and detecting EXOs to diagnose AD before the development of advanced symptoms. This review is not reiterative literature but will discuss why EXOs have strong potential in treating AD and how they can be used as a tool to predict and diagnose this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Exosomes exhibit low immunogenicity and high biocompatibility, thereby minimizing the risk of immune responses and facilitating efficient delivery to the brain [89, 90].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288 · cited 2×
“For 218 of the 467 mature microRNAs examined, microRNA from ovarian tumor cells and EXOs from similar individuals were positive [101].”
BackgroundRetractedCirculating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186 · cited 1×
“The great diagnostic potential of EXOs lies in the fact that these nanosized vesicles have a specific profile of biomolecule content from the cell of origin, similar to proteins, nucleic acids, and lipids; they act as a “fingerprint” or a “signature” of parent cells and can reflect the pathological conditions when cha…”
BackgroundIsolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 2×
“Immuno-Isolation • High-purity isolation • Knowledge of the exosomal surface components is a challenge in this method • Scale-up [56,61]”
MethodDelivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 3×
“For example, modified surface proteins with overexpressed Lamp2b bound to the neuron-specific rabies virus glycoprotein (RVG) peptide were found to enhance CNS penetration and targeting capabilities [47].”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“Recent studies prove that soluble Aβ oligomeric forms can be a potential player in AD progression [24].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Tetraspanins organize the multimolecular membrane complexes, cell adhesion, fusion, signaling, and metastatic processes [50,51], and they were also reported to serve as a facilitative component in infection processes, promoting viral penetration and exit [52].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Introduction to NF-κB: players, pathways, perspectives
Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209954 · Cited by 2,222 · cited 1×
“NF-κB is found almost in all cell types and is involved in cellular signaling and stimuli such as cytokines, stress, free radicals, oxidized-LDL, and microbial antigens [87].”
BackgroundExosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Progress in Exosome Isolation Techniques
Li, P., Kaslan, M., Lee, S. H., Yao, J., & Gao, Z. (2017) · Theranostics · doi:10.7150/thno.18133 · Cited by 1,948 · cited 3×
“Ultracentrifugation (UC) is the gold-standard process for isolating and purifying EXOs and EXO-like particles because of its non-complexity and low cost; although the procedure improves the purity, it decreases the yield of separated EXOs [56,57].”
BackgroundA blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Optimized exosome isolation protocol for cell culture supernatant and human plasma
Lobb, R. J., Becker, M., Wen Wen, S., Wong, C. S. F., Wiegmans, A. P., Leimgruber, A., & Möller, A. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27031 · Cited by 1,705
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 2×
“Asai et al., 2015 suggested that microglia help to spread the harmful tau proteins through an EXO-based mechanism that releases tau proteins in AD [34,35].”
BackgroundA review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578 · cited 2×
“The presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain autopsies of AD patients revealed them as the critical players in the pathophysiology of AD [4].”
BackgroundZhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356 · cited 1×
“Due to the nanometer-sized diameter and permeability, EXOs can facilitate the penetration of the BBB and therefore engage in various signaling events, providing insight into the development and management of brain disorders [48].”
BackgroundHa, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346 · cited 3×
“Being spherically shaped nanoparticles ranging from 30 to 150 nm [14] and structurally similar to nanoliposomes, EXOs are being implemented, in nanomedicine, as safe, nonimmunogenic drug-carrying vehicles [9,10].”
BackgroundAlzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 1×
“AD-associated peptides were first discovered in EXOs while tracking APP cleavage events [26].”
BackgroundAstrocyte-endothelial Interactions and Blood-Brain Barrier Permeability*
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00064.x · Cited by 1,168
Engineering exosomes as refined biological nanoplatforms for drug delivery
Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.12 · Cited by 1,163 · cited 2×
“Applying these strategies will affect both the loading efficiency and overall system efficacy [63].”
Background(1987) · PubMed · Cited by 1,147
Tau in Alzheimer Disease and Related Tauopathies
Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,127
Role of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V. P., Lockman, P., & Bai, S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1593-y · Cited by 975 · cited 2×
“, 2015 proposed the potential role of the exosomal membrane tetraspanins in passing to the brain [49].”
BackgroundFiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., Sisto, F., Doglia, S. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.042 · Cited by 846 · cited 1×
“Moreover, the incubated drug with the host cells is not a reliable approach for their low yield, despite its observed benefit in releasing EXOs carrying the active pharmaceuticals (APs), as demonstrated with Paclitaxel in mesenchymal stromal cells [56,64].”
BackgroundAlonso, A. D. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 827
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
Nilsson, J., Skog, J., Nordstrand, A., Baranov, V, Mincheva-Nilsson, L., Breakefield, X. O., & Widmark, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605058 · Cited by 776
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Fuhrmann, G., Serio, A., Mazo, M., Nair, R., & Stevens, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.029 · Cited by 742 · cited 1×
“, 2014 reported saponin-assisted loading as 11fold more efficient for hydrophilic porphyrins than passive loading [65].”
BackgroundNF-κB functions in synaptic signaling and behavior
Meffert, M. K., Chang, J. M., Wiltgen, B. J., Fanselow, M. S., & Baltimore, D. (2003) · Nature Neuroscience · doi:10.1038/nn1110 · Cited by 690 · cited 1×
“NF-κB has been associated with the formation of synaptic plasticity and memory as well [88].”
BackgroundApplication of exosomes as liquid biopsy in clinical diagnosis
Zhou, B., Xu, K., Zheng, X., Chen, T., Wang, J., Song, Y., Shao, Y., & Zheng, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00258-9 · Cited by 685
The release and trans-synaptic transmission of Tau via exosomes
Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0143-y · Cited by 674
Kanwar, S. S., Dunlay, C. J., Simeone, D. M., & Nagrath, S. (2014) · Lab Chip · doi:10.1039/c4lc00136b · Cited by 662
Tau protein function in living cells.
Drubin, D. G., & Kirschner, M. W. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.6.2739 · Cited by 652
Sphingolipid-modulated Exosome Secretion Promotes Clearance of Amyloid-β by Microglia
Yuyama, K., Sun, H., Mitsutake, S., & Igarashi, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324616 · Cited by 595 · cited 2×
“Although EXOs reconstitute an essential route for the clearance of Aβ from the cell, they might pose a risk to the nearby cells by increasing Aβ aggregation potential [28].”
BackgroundRecent advancements in the use of exosomes as drug delivery systems
Bunggulawa, E. J., Wang, W., Yin, T., Wang, N., Durkan, C., Wang, Y., & Wang, G. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0403-9 · Cited by 589 · cited 3×
“Moreover, EXOs were tested as successful delivery systems for therapeutic drugs, proteins, and genetic material, including nucleic acids and their derivatives, and thus can interfere with several metabolic paths of AD [9].”
BackgroundCirculating miRNAs are correlated with tumor progression in prostate cancer
Brase, J. C., Johannes, M., Schlomm, T., Fälth, M., Haese, A., Steuber, T., Beissbarth, T., Kuner, R., & Sültmann, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25376 · Cited by 587
Exosomes in bodily fluids are a highly stable resource of disease biomarkers
Boukouris, S., & Mathivanan, S. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400114 · Cited by 586
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes
Katsuda, T., Tsuchiya, R., Kosaka, N., Yoshioka, Y., Takagaki, K., Oki, K., Takeshita, F., Sakai, Y., Kuroda, M., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep01197 · Cited by 565 · cited 1×
“EXOs are among the stem cell secretome, where exciting findings showed that EXOs derived from dental pulp stem cells (DPSCs) [74], bone marrow stromal cells (BMSCs), and adiposederived stem cells (ADSCs) contain neprilysin and insulin-degrading enzyme [75,76], whose functions are to degrade Aβ [77].”
BackgroundExosomes: Novel Biomarkers for Clinical Diagnosis
Lin, J., Li, J., Huang, B., Liu, J., Chen, X., Chen, X.-M., Xu, Y.-M., Huang, L.-F., & Wang, X.-Z. (2015) · The Scientific World Journal · doi:10.1155/2015/657086 · Cited by 562 · cited 4×
“found higher levels of fetuin-A, a urinary exosomal protein, in patients with acute kidney injury (AKI) [17,18].”
BackgroundInfluentialAmyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537 · cited 1×
“tangle of Aβ oligomers and amyloid fibrils forming regularly arranged aggregates [23].”
BackgroundAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · cited 2×
“2018, provided supportive evidence by showing Aβ oligomer-rich EXOs in Alzheimer’s brains and thus proved that EXOs could act as transfer vesicles among neurons [29].”
BackgroundNeuroprotective effects of curcumin
Cole, G. M., Teter, B., & Frautschy, S. A. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_8 · Cited by 516 · cited 1×
“To test the efficiency of the new model, Curcumin (Cur), which possesses anti-inflammatory action and the potential capacity to halt oxidative stress and Aβ deposits [73], was chosen to be loaded in this EXO-liposome model.”
MethodCerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Pardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447 · cited 9×
“However, further clinical applications of Que were stopped because of their poor solubility, reduced systematic concentration, and inability to penetrate the BBB [70,71].”
BackgroundInfluentialTanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., & Baba, H. (2013) · Cancer · doi:10.1002/cncr.27895 · Cited by 446
Zhou, H., Pisitkun, T., Aponte, A., Yuen, P. S. T., Hoffert, J. D., Yasuda, H., Hu, X., Chawla, L., Shen, R.-F., Knepper, M. A., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001874 · Cited by 445 · cited 3×
“found higher levels of fetuin-A, a urinary exosomal protein, in patients with acute kidney injury (AKI) [17,18].”
BackgroundHong, B. S., Cho, J.-H., Kim, H., Choi, E.-J., Rho, S., Kim, J., Kim, J. H., Choi, D.-S., Kim, Y.-K., Hwang, D., et al. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-556 · Cited by 443
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441 · cited 9×
“However, further clinical applications of Que were stopped because of their poor solubility, reduced systematic concentration, and inability to penetrate the BBB [70,71].”
BackgroundInfluentialNeuronal Exosomal miRNA-dependent Translational Regulation of Astroglial Glutamate Transporter GLT1
Morel, L., Regan, M., Higashimori, H., Ng, S. K., Esau, C., Vidensky, S., Rothstein, J., & Yang, Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410944 · Cited by 430 · cited 1×
“In another study, the neuronal–glial delivery of miR124a through EXOs resulted in the upregulation of the excitatory amino acid transporter 2 (EAAT2, rodent analogue GLT1) on the astrocytes’ surface, enhancing glutamate uptake, which is critical for preserving intact cognitive function in this case [81,82].”
BackgroundInflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427 · cited 1×
“These plaques stimulate the immune system to generate an inflammatory response that damages the surrounding neurons [5].”
BackgroundExtracellular vesicles: novel promising delivery systems for therapy of brain diseases.
Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 418 · cited 4×
“Being spherically shaped nanoparticles ranging from 30 to 150 nm [14] and structurally similar to nanoliposomes, EXOs are being implemented, in nanomedicine, as safe, nonimmunogenic drug-carrying vehicles [9,10].”
BackgroundMethodInfluentialCentral role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410 · cited 1×
“Aβ peptides are proteolytic derivatives of APP; this process can take place in a different position in the cell and is regulated by the endosomal pathway, which is likewise crucial for forming EXOs [25].”
BackgroundAnatomy and physiology of the blood-brain barrier
Serlin, Y., Shelef, I., Knyazer, B., & Friedman, A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.01.002 · Cited by 397 · cited 1×
“The structure of the BBB is a complicated system made up of various cells, including astroglia, perivascular macrophages, basal lamella, pericyte, and endothelial cells, besides the presence of multidrug transporters, efflux pumps, ectozymes, and endozymes [43,44].”
BackgroundExosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools
Li, S.-P., Lin, Z.-X., Jiang, X.-Y., & Yu, X.-Y. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.178 · Cited by 390 · cited 1×
“and cargo, such as proteins, mRNAs, miRNAs, and lipids [53].”
BackgroundCui, G., Wu, J., Mou, F., Xie, W., Wang, F., Wang, Q., Fang, J., Xu, Y., Dong, Y., Liu, J., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201700600r · Cited by 387
Winston, C. N., Goetzl, E. J., Akers, J. C., Carter, B. S., Rockenstein, E. M., Galasko, D., Masliah, E., & Rissman, R. A. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.04.001 · Cited by 379
Jia, L., Qiu, Q., Zhang, H., Chu, L., Du, Y., Zhang, J., Zhou, C., Liang, F., Shi, S., Wang, S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.002 · Cited by 373
The emerging role of exosomes in mental disorders
Saeedi, S., Israel, S., Nagy, C., & Turecki, G. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0459-9 · Cited by 370
Yuyama, K., Sun, H., Sakai, S., Mitsutake, S., Okada, M., Tahara, H., Furukawa, J.-I., Fujitani, N., Shinohara, Y., & Igarashi, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577213 · Cited by 333 · cited 1×
“Interestingly, Yuyama et al., 2014, declared the role of EXOs as Aβ scavengers, mediated through Aβ-glycan and EXO-glycosphingolipid attachment, leading to a significant reduction in Aβ count and therefore the mitigation of AD pathophysiology [83].”
BackgroundPlasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
Khan, S., Jutzy, J. M. S., Valenzuela, M. M. A., Turay, D., Aspe, J. R., Ashok, A., Mirshahidi, S., Mercola, D., Lilly, M. B., & Wall, N. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046737 · Cited by 331
The Psychiatric Symptoms of Alzheimer's Disease
Merriam, A. E., Aronson, M. K., Gaston, P., Wey, S., & Katz, I. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb03427.x · Cited by 319
Exosomes/miRNAs as mediating cell-based therapy of stroke
Xin, H., Li, Y., & Chopp, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00377 · Cited by 297
Exosomes in the Pathology of Neurodegenerative Diseases
Howitt, J., & Hill, A. F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.757955 · Cited by 288
Cell to Cell Signalling via Exosomes Through esRNA
Lotvall, J., & Valadi, H. (2007) · Cell Adhesion & Migration · doi:10.4161/cam.1.3.5114 · Cited by 283
Urinary exosomal transcription factors, a new class of biomarkers for renal disease
Zhou, H., Cheruvanky, A., Hu, X., Matsumoto, T., Hiramatsu, N., Cho, M. E., Berger, A., Leelahavanichkul, A., Doi, K., Chawla, L. S., et al. (2008) · Kidney International · doi:10.1038/ki.2008.206 · Cited by 276 · cited 1×
“noticed that the activated transcription factor-3 (ATF3) was linked to AKI rather than chronic or control cases, implying that both increased exosomal fetuin-A and ATF3 can be effective biomarkers in AKI diagnosis [18,19].”
BackgroundWiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04404.x · Cited by 263
Takeshita, N., Hoshino, I., Mori, M., Akutsu, Y., Hanari, N., Yoneyama, Y., Ikeda, N., Isozaki, Y., Maruyama, T., Akanuma, N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.8 · Cited by 262
Neuroprotective Effect of Quercetin Against the Detrimental Effects of LPS in the Adult Mouse Brain
Khan, A., Ali, T., Rehman, S. U., Khan, M. S., Alam, S. I., Ikram, M., Muhammad, T., Saeed, K., Badshah, H., & Kim, M. O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01383 · Cited by 261 · cited 1×
“Quercetin (Que), a naturally occurring cognitive enhancer known for its neuroprotective and anti-inflammatory actions [68], has been reported to suppress tau-mediated AD”
BackgroundNaturally Occurring Exosome Vesicles as Potential Delivery Vehicle for Bioactive Compounds
Akuma, P., Okagu, O. D., & Udenigwe, C. C. (2019) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2019.00023 · Cited by 261 · cited 10×
“On the other hand, active loading involves subjecting EXOs to shear stress that temporarily affects the membrane permeability, resulting in APs’ diffusion into the vesicle [56].”
BackgroundMethodInfluentialUnlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260 · cited 1×
“Improving CNS exosomal delivery through bio-engineered molecules and surface modification has acquired growing interest [46].”
BackgroundSynaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
Sharples, R. A., Vella, L. J., Nisbet, R. M., Naylor, R., Perez, K., Barnham, K. J., Masters, C. L., & Hill, A. F. (2008) · The FASEB Journal · doi:10.1096/fj.07-9357com · Cited by 254 · cited 1×
“EXOs have consistently contained APP and C-terminal fragments of APP (CTFs-APP) and numerous proteases involved in APP processing [27].”
BackgroundExosomal proteins as prognostic biomarkers in non‐small cell lung cancer
Sandfeld-Paulsen, B., Aggerholm-Pedersen, N., Bæk, R., Jakobsen, K. R., Meldgaard, P., Folkersen, B. H., Rasmussen, T. R., Varming, K., Jørgensen, M. M., & Sorensen, B. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.10.003 · Cited by 250 · cited 1×
“In particular, the study showed that rising NYESO-1, EGFR, and PLAP concentration levels are predictive indicators of poor prognosis [99].”
BackgroundBlood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage
Jia, L., Zhu, M., Kong, C., Pang, Y., Zhang, H., Qiu, Q., Wei, C., Tang, Y., Wang, Q., Li, Y., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12166 · Cited by 250
Qi, Y., Guo, L., Jiang, Y., Shi, Y., Sui, H., & Zhao, L. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1762262 · Cited by 239 · cited 11×
“However, further clinical applications of Que were stopped because of their poor solubility, reduced systematic concentration, and inability to penetrate the BBB [70,71].”
BackgroundMethodInfluentialIntracellular and Extracellular MicroRNAs in Breast Cancer
Corcoran, C., Friel, A. M., Duffy, M. J., Crown, J., & O'Driscoll, L. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.150730 · Cited by 225
Advances in exosomes technology
Chen, B.-Y., Sung, C. W.-H., Chen, C., Cheng, C.-M., Lin, D. P.-C., Huang, C.-T., & Hsu, M.-Y. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.021 · Cited by 223 · cited 6×
“Paper-Based Immunoaffinity • Ultra-pure yield • Requires minimal sample amount • Simple and fast • The specificity of the used antibodies governs the selection process • Low yield [60,62]”
BackgroundMethodInfluentialRole of Exosomes in Central Nervous System Diseases
Liu, W., Bai, X., Zhang, A., Huang, J., Xu, S., & Zhang, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00240 · Cited by 221
Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Dong, H., Li, J., Huang, L., Chen, X., Li, D., Wang, T., Hu, C., Xu, J., Zhang, C., Zen, K., et al. (2015) · Disease Markers · doi:10.1155/2015/625659 · Cited by 211
LIU, C.-G., SONG, J., ZHANG, Y.-Q., & WANG, P.-C. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2484 · Cited by 201
Lin, S.-L., Miller, J. D., & Ying, S.-Y. (2006) · BioMed Research International · doi:10.1155/jbb/2006/26818 · Cited by 188 · cited 1×
“Non-coding regions on RNA strands (introns) such as miRNA [78] are regulatory codons involved in protein expression.”
BackgroundExosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo
An, K., Klyubin, I., Kim, Y., Jung, J. H., Mably, A. J., O’Dowd, S. T., Lynch, T., Kanmert, D., Lemere, C. A., Finan, G. M., et al. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-47 · Cited by 185
Role of Mitochondrial Amyloid-β in Alzheimer's Disease
Chen, J. X., & Yan, S. S. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100357 · Cited by 183
Li, D., Zhang, P., Yao, X., Li, H., Shen, H., Li, X., Wu, J., & Lu, X. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00845 · Cited by 180 · cited 1×
“Furthermore, EXOs can penetrate tissues, disperse into the blood, and possess a unique capacity to pass the BBB, making them perfect carriers for drug and genetic components to treat neurological disorders [66,67].”
BackgroundDiagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Soares Martins, T., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., da Cruz e Silva, O. A. B., & Henriques, A. G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 174 · cited 1×
“Further, defective hyperphosphorylation and misfolded tau proteins yield intracellular NFTs and impair signaling across the neurons [6].”
BackgroundChen, Y.-A., Lu, C.-H., Ke, C.-C., Chiu, S.-J., Jeng, F.-S., Chang, C.-W., Yang, B.-H., & Liu, R.-S. (2021) · Biomedicines · doi:10.3390/biomedicines9060594 · Cited by 167 · cited 2×
“Chen et al., 2021 illustrated the curative mechanism of MSC-EXOs and proposed a cell-free MSC-EXO-based therapy method for treating AD.”
BackgroundMethodVisinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease
Tarawneh, R., D'Angelo, G., Macy, E., Xiong, C., Carter, D., Cairns, N. J., Fagan, A. M., Head, D., Mintun, M. A., Ladenson, J. H., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22448 · Cited by 165
Exosomes in Alzheimer's disease
Malm, T., Loppi, S. H., & Kanninen, K. M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.011 · Cited by 163
Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells
Huang, S.-H., Li, Y., Zhang, J., Rong, J., & Ye, S. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.789905 · Cited by 154
Bulloj, A., Leal, M. C., Xu, H., Castaño, E. M., & Morelli, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1206 · Cited by 149 · cited 1×
“EXOs are among the stem cell secretome, where exciting findings showed that EXOs derived from dental pulp stem cells (DPSCs) [74], bone marrow stromal cells (BMSCs), and adiposederived stem cells (ADSCs) contain neprilysin and insulin-degrading enzyme [75,76], whose functions are to degrade Aβ [77].”
BackgroundClark, D. J., Fondrie, W. E., Yang, A. J., & Mao, L. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.12.023 · Cited by 149 · cited 6×
“Exosomal EGFR is one of the NSCLC membrane-bound proteins.”
MethodInfluentialFerreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L.-O., SarrÃa, A., & Serrano-Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 142
Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations
Li, K., Wei, Q., Liu, F., Hu, F., Xie, A., Zhu, L., & Liu, D. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0533-3 · Cited by 142
Lab-on-Chip for Exosomes and Microvesicles Detection and Characterization
Chiriacò, M. S., Bianco, M., Nigro, A., Primiceri, E., Ferrara, F., Romano, A., Quattrini, A., Furlan, R., Arima, V., & Maruccio, G. (2018) · Sensors · doi:10.3390/s18103175 · Cited by 130
Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
Farlow, M. R., Miller, M. L., & Pejovic, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 129 · cited 1×
“AD treatment generally shares one target by increasing the Acetyl Choline level by preventing its degradation and thus preserving intact memory and cognitive functions [7].”
BackgroundNeuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
The role of exosomes in the pathogenesis of Alzheimer’ disease
Xiao, T., Zhang, W., Jiao, B., Pan, C.-Z., Liu, X., & Shen, L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0072-x · Cited by 126
Astrocyte–endothelial interactions and blood–brain barrier permeability
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00047_13.x · Cited by 126
The Role of Microglia in the Spread of Tau: Relevance for Tauopathies
Perea, J. R., Llorens-Martín, M., Ávila, J., & Bolós, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00172 · Cited by 122
Ding, L., Yang, X., Gao, Z., Effah, C. Y., Zhang, X., Wu, Y., & Qu, L. (2021) · Small · doi:10.1002/smll.202007174 · Cited by 119
Siedlecki-Wullich, D., Català-Solsona, J., Fábregas, C., Hernández, I., Clarimon, J., Lleó, A., Boada, M., Saura, C. A., Rodríguez-Álvarez, J., & Miñano-Molina, A. J. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0501-4 · Cited by 118
Exosomes as Carriers of Alzheimer's Amyloid-ß
Yuyama, K., & Igarashi, Y. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00229 · Cited by 114 · cited 1×
“Furthermore, EXOs can penetrate tissues, disperse into the blood, and possess a unique capacity to pass the BBB, making them perfect carriers for drug and genetic components to treat neurological disorders [66,67].”
BackgroundQuercetin Loaded Nanoparticles in Targeting Cancer: Recent Development
Vinayak, M., & Maurya, A. K. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190705150214 · Cited by 112 · cited 9×
“However, further clinical applications of Que were stopped because of their poor solubility, reduced systematic concentration, and inability to penetrate the BBB [70,71].”
BackgroundInfluentialAhmed, N. E.-M. B., Murakami, M., Hirose, Y., & Nakashima, M. (2016) · Stem Cells International · doi:10.1155/2016/8102478 · Cited by 99 · cited 2×
“Moreover, these EXOs were capable of Aβ1–42 degradation and attenuated their neurotoxic effects in SH-SY5Y neuroblastoma cells in vitro [75].”
BackgroundNovel concept of exosome-like liposomes for the treatment of Alzheimer's disease
Fernandes, M., Lopes, I., Magalhães, L., Sárria, M. P., Machado, R., Sousa, J. C., Botelho, C., Teixeira, J., & Gomes, A. C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.018 · Cited by 95 · cited 2×
“The new model showed promising results as the encapsulation proficiency of Cur was up to approximately 94%, Cur-loaded liposomes showed no cytotoxic activity (up to 20 μM Cur and 200 μM of exo-liposomes), and the overall significance was to mitigate the induced oxidative stress in neuronal cells, indicating their neur…”
BackgroundXian, J., Su, W., Liu, L., Rao, B., Lin, M., Feng, Y., Qiu, F., Chen, J., Zhou, Q., Zhao, Z., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.05.011 · Cited by 94 · cited 1×
“RNA-sequencing tests were conducted among three pairs of patients with NSCLC and controls [100].”
MethodPoupardin, R., Wolf, M., & Strunk, D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113872 · Cited by 94
Extracellular Vesicles and the Promise of Continuous Liquid Biopsies
Armstrong, D. L., & Wildman, D. E. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.05.21 · Cited by 93
Peterson, A. R., & Binder, D. K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00164 · Cited by 87 · cited 1×
“In another study, the neuronal–glial delivery of miR124a through EXOs resulted in the upregulation of the excitatory amino acid transporter 2 (EAAT2, rodent analogue GLT1) on the astrocytes’ surface, enhancing glutamate uptake, which is critical for preserving intact cognitive function in this case [81,82].”
BackgroundTetraspanins: Architects of Viral Entry and Exit Platforms
Hantak, M. P., Qing, E., Earnest, J. T., & Gallagher, T. (2019) · Journal of Virology · doi:10.1128/jvi.01429-17 · Cited by 86 · cited 1×
“Tetraspanins organize the multimolecular membrane complexes, cell adhesion, fusion, signaling, and metastatic processes [50,51], and they were also reported to serve as a facilitative component in infection processes, promoting viral penetration and exit [52].”
BackgroundPeng, H., Liang, Z., Piao, H. Z., Ji, X., Wang, Y., Liu, Y., Liu, R., & Liu, J. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9490-y · Cited by 81 · cited 1×
“Human adipose-derived MSCs secreted EXOs that exerted direct neuroprotective effects by preventing neuronal apoptosis, thus supporting the regeneration and repair of the CNS and hence restoring bioenergy after exhaustion due to glutamate excitotoxicity [86].”
BackgroundTargetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer’s Disease
Yin, Q., Ji, X., Lv, R., Pei, J.-J., Du, Y., Shen, C., & Hou, X. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s240400 · Cited by 77 · cited 1×
“EXOs from the neuronal genetically modified neuroblastoma cell line (N2a cells) can neutralize Aβ-induced disruptions in synaptic plasticity and prevent Aβ-induced neuronal apoptosis [84,85].”
BackgroundKatsuda, T., Oki, K., & Ochiya, T. (2014) · Methods in molecular biology · doi:10.1007/7651_2014_98 · Cited by 76 · cited 1×
“EXOs are among the stem cell secretome, where exciting findings showed that EXOs derived from dental pulp stem cells (DPSCs) [74], bone marrow stromal cells (BMSCs), and adiposederived stem cells (ADSCs) contain neprilysin and insulin-degrading enzyme [75,76], whose functions are to degrade Aβ [77].”
BackgroundExosomal biomarkers in Down syndrome and Alzheimer's disease
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A.-C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 76
Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease
Watson, L. S., Hamlett, E. D., Stone, T. D., & Sims-Robinson, C. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0317-5 · Cited by 74
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
Abner, E. L., Jicha, G. A., Shaw, L. M., Trojanowski, J. Q., & Goetzl, E. J. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.309 · Cited by 73
Zhao, A., Li, Y., Yan, Y., Qiu, Y., Li, B., Xu, W. L., Wang, Y., Liu, J., & Deng, Y. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00210-5 · Cited by 71
Exosomes: A New Weapon to Treat the Central Nervous System
Braccioli, L., van Velthoven, C. T. J., & Heijnen, C. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8504-9 · Cited by 69 · cited 4×
“The active cleavage of APP triggered by β-and γ-secretase within early endosomes yields Aβ to the MVBs.”
BackgroundInfluentialExosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer’s Disease
Manna, I., De Benedittis, S., Quattrone, A., Maisano, D., Iaccino, E., & Quattrone, A. (2020) · Pharmaceuticals · doi:10.3390/ph13090243 · Cited by 68
Exosomes: a novel therapeutic target for Alzheimer’s disease?
Cai, Z.-Y., Ke, Z.-Y., Xiao, M., & Quazi, S. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.232490 · Cited by 64 · cited 3×
“Further, EXOs possess a significant role in neuroinflammation because they are a natural nanocarrier of neurotoxic inflammatory molecules and mediate intercellular communication between cells; they also release Aβ, thus accelerating amyloid plaque formation and facilitating the progression of inflammation in brain cel…”
BackgroundInfluentialRani, K., Rastogi, S., Vishwakarma, P., Bharti, P. S., Sharma, V., Renu, K., Modi, G. P., Vishnu, V. Y., Chatterjee, P., Dey, A. B., et al. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108980 · Cited by 64
Meng, Y., Asghari, M. H., Aslan, M. K., Yılmaz, A., Mateescu, B., Stavrakis, S., & deMello, A. J. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126110 · Cited by 62
Development and comparative analysis of human urine exosome isolation strategies
Cho, S., Yang, H. C., & Rhee, W. J. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.09.017 · Cited by 60
A Pilot Study of Urinary Exosomes in Alzheimer’s Disease
Sun, R., Wang, H., Shi, Y., Gao, D., Sun, Z., Chen, Z., Jiang, H., & Zhang, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505851 · Cited by 59
Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease
Gu, D., Liu, F., Meng, M., Zhang, L., Gordon, M. L., Wang, Y., Cai, L., & Zhang, N. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51155 · Cited by 59
ABCA1‐Labeled Exosomes in Serum Contain Higher MicroRNA‐193b Levels in Alzheimer’s Disease
Liu, C., Zhao, Y., Lu, Y., & Wang, P. (2021) · BioMed Research International · doi:10.1155/2021/5450397 · Cited by 55
Kuo, Y.-C., Chen, C.-L., & Rajesh, R. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.065 · Cited by 54 · cited 1×
“pathophysiology and, to a significant extent, Aβ plaques by inhibiting amyloid production [69].”
BackgroundSize Exclusion Chromatography: A Simple and Reliable Method for Exosome Purification
Lobb, R. J., & Möller, A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7253-1_9 · Cited by 52 · cited 2×
“Size-exclusion liquid chromatography (SEC) helps to isolate EXOs based on size differences; it is suitable with purification from serum or plasma, does not require pelleting EXOs at high speeds, and produces a highly purified product [59].”
BackgroundExosomes Transfer Among Different Species Cells and Mediating miRNAs Delivery
Zhou, Y., Tian, T., Zhu, Y., Ali, D. J., Hu, F., Qi, Y., Sun, B., & Xiao, Z. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26077 · Cited by 50 · cited 1×
“The EXO-based cargo delivery system is thought to be mediated by endocytosis, where EXOs release their cargo after entering the targeted cell and may proceed to other physiological and pathological functions [13].”
BackgroundDeficient neurotrophic factors of CSPG4‐type neural cell exosomes in Alzheimer disease
Goetzl, E. J., Nogueras-Ortiz, C., Mustapic, M., Mullins, R. J., Abner, E. L., Schwartz, J. B., & Kapogiannis, D. (2019) · The FASEB Journal · doi:10.1096/fj.201801001 · Cited by 48
Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease
Zhang, M., Han, W., Xu, Y., Li, D., & Xue, Q. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290925 · Cited by 48
Gervaise-Henry, C., Watfa, G., Albuisson, E., Kolodziej, A., Dousset, B., Olivier, J.-L., Jonveaux, T. R., & Malaplate-Armand, C. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160865 · Cited by 46
Manczak, M., & Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.008 · Cited by 41 · cited 1×
“Furthermore, any alteration in their expression can propagate disease conditions due to dysregulated, non-functioning codons, as in the case of many neurodegenerative disorders [79]; thus, they can be incorporated into AD gene silencing treatment regimens [80].”
BackgroundLongobardi, A., Benussi, L., Nicsanu, R., Bellini, S., Ferrari, C., Saraceno, C., Zanardini, R., Catania, M., Fede, G. D., Squitti, R., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667369 · Cited by 38
Lakshmi, S., Essa, M. M., Hartman, R. E., Guillemin, G. J., Sureshkumar, S., & Elumalai, P. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03111-1 · Cited by 36 · cited 1×
“Figure 1 illustrates how EXOs can carry Aβ oligomers and tau protein, whose accumulation is responsible for causing AD [21,22].”
BackgroundMicroRNA-135a in ABCA1-labeled Exosome is a Serum Biomarker Candidate for Alzheimer's Disease.
Liu, C. G., Meng, S., Li, Y., Lu, Y., Zhao, Y., & Wang, P. C. (2021) · PubMed · doi:10.3967/bes2021.004 · Cited by 36
Isolation of Exosome Nanoparticles from Human Cerebrospinal Fluid for Proteomic Analysis
Li, M., Huang, L., Chen, J., Ni, F., Zhang, Y., & Liu, F. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c02622 · Cited by 34
Xing, W., Gao, W., Lv, X., Xu, X., Zhang, Z., Yan, J., Mao, G., & Bu, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.637218 · Cited by 27
The Microfluidic Toolbox for Analyzing Exosome Biomarkers of Aging
DeCastro, J., Littig, J., Chou, P. P., Mack‐Onyeike, J., Srinivasan, A., Conboy, M. J., Conboy, I. M., & Aran, K. (2021) · Molecules · doi:10.3390/molecules26030535 · Cited by 22
The Role of Aptamer Loaded Exosome Complexes in the Neurodegenerative Diseases
Sekhon, S. S., Ahn, G., Park, G., Park, D. Y., Lee, S., Ahn, J., & Kim, Y. (2019) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-019-0392-6 · Cited by 18
Does metabolic failure at the synapse cause Alzheimer’s disease?
Engel, P. A. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.10.013 · Cited by 15
Hsu, M., Chiu, C.-C., Wang, J.-Y., Huang, C., Huang, Y., Liou, J.-C., Chen, C., Chen, H., & Cheng, C. (2018) · Nanomaterials · doi:10.3390/nano8050310 · Cited by 14 · cited 2×
“Paper-Based Immunoaffinity • Ultra-pure yield • Requires minimal sample amount • Simple and fast • The specificity of the used antibodies governs the selection process • Low yield [60,62]”
BackgroundMechanismen der Alzheimer-Krankheit: Neuronale Hyper- und Hypoaktivität als neue Therapieziele
Busche, M. A., Staufenbiel, M., Willem, M., Haass, C., & Förstl, H. (2016) · Der Nervenarzt · doi:10.1007/s00115-015-0041-5 · Cited by 7
Roles of tetraspanin proteins in cell and tumor biology
Lazo, P. A. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/44574 · Cited by 4 · cited 1×
“Tetraspanins organize the multimolecular membrane complexes, cell adhesion, fusion, signaling, and metastatic processes [50,51], and they were also reported to serve as a facilitative component in infection processes, promoting viral penetration and exit [52].”
Background(2018) · doi:10.3967/bes2018.011
Cited by
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
“Exosomes, which are naturally produced by human cells, are emerging as a new generation of highly protective nanoplatforms for efficient drug delivery [172].”
BackgroundSelf-citationUnderstanding exosomes: Part 2—Emerging leaders in regenerative medicine
Miron, R. J., Estrin, N. E., Sculean, A., & Zhang, Y. (2024) · Periodontology 2000 · doi:10.1111/prd.12561 · Cited by 98
The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
Iranpanah, A., Kooshki, L., Moradi, S. Z., Saso, L., Fakhri, S., & Khan, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031006 · Cited by 64
Production and Utility of Extracellular Vesicles with 3D Culture Methods
Ester, M. C., & Day, R. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020663 · Cited by 73
Exosomes in brain diseases: Pathogenesis and therapeutic targets
Si, Q., Wu, L., Pang, D., & Jiang, P. (2023) · MedComm · doi:10.1002/mco2.287 · Cited by 69
Metadata
- Authors
- Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., Emam, S. E., Hassan, A. E. A., & Attia, M. S.
- Affiliations
- Zagazig University (EG)
- Chitkara University (IN)
- Corresponding author
- Attia, Mohamed S.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-10-06
- Volume
- 22
- Issue
- 19
- Pages
- 10794
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8509246
- OpenAlex
- W3202186439
- Cited by
- 81
- References
- 154
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 19 · 2023: 17 · 2022: 14 · 2021: 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- exosomes, Alzheimer's disease, extracellular vesicles, drug delivery, neurodegenerative diseases, biomarkers, early diagnosis, microfluidics, exosome isolation, immunogenicity, therapeutics
- MeSH terms
- Alzheimer Disease, Animals, Humans, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.